1800-272-662
Shopping Cart 0
countryflagAU
Login

Abeona Therapeutics Inc

Healthcare US ABEO

5.14USD
-0.02(0.39%)

Last update at 2026-03-10T20:00:00Z

Day Range

5.115.32
LowHigh

52 Week Range

3.059.01
LowHigh

Fundamentals

  • Previous Close 5.16
  • Market Cap257.35M
  • Volume2086714
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-54.74700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -28.00100M
  • Diluted EPS TTM-2.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -39.69600M -84.93600M -84.23400M -76.28200M -56.67100M
Minority interest - - - - -
Net income -31.80900M -88.60600M -88.34900M -76.68200M -56.67100M
Selling general administrative 17.26M 22.80M 23.78M 20.70M 20.11M
Selling and marketing expenses - - - - -
Gross profit 0.96M 3.00M 10.00M -48.56600M 3.00M
Reconciled depreciation 4.58M 3.25M 4.59M 7.82M 2.36M
Ebit -45.25700M -89.83600M -81.42000M -77.09000M -56.66000M
Ebitda -44.68500M -54.05100M -42.61700M -67.20500M -54.30000M
Depreciation and amortization 0.57M 35.78M 38.80M 9.88M 2.36M
Non operating income net other - - - - 1.51M
Operating income -45.25700M -89.83600M -81.42000M -77.09000M -58.16600M
Other operating expenses 46.67M 60.37M 58.50M 77.09M 61.16M
Interest expense 0.74M 3.67M 4.12M 0.40M 0.01M
Tax provision - - - - -
Interest income 0.43M 0.07M 1.30M 1.21M 1.51M
Net interest income -0.30500M -3.60100M -2.81400M 0.81M 1.50M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -7.88700M 3.67M 4.12M 0.40M 1.51M
Total revenue 1.41M 3.00M 10.00M 0.00000M 3.00M
Total operating expenses 46.22M 60.37M 58.50M 77.09M 61.16M
Cost of revenue 0.45M - - 48.57M 38.70M
Total other income expense net 5.56M 4.90M -2.81400M 0.81M 1.50M
Discontinued operations - - - - -
Net income from continuing ops -39.69600M -84.93600M -84.23400M -77.49000M -56.67100M
Net income applicable to common shares -43.47800M -84.93600M -84.23400M -76.28200M -56.67100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 64.00M 64.21M 79.59M 151.20M 223.38M
Intangible assets - - 1.38M 1.50M 36.18M
Earning assets - - - - -
Other current assets 0.73M 0.42M 7.38M 2.71M 3.13M
Total liab 49.18M 37.45M 28.21M 48.65M 44.95M
Total stockholder equity 14.83M 26.76M 51.38M 102.55M 178.43M
Deferred long term liab - - - - -
Other current liab 10.57M 4.20M 10.18M 34.92M 32.94M
Common stock 0.27M 0.18M 1.47M 0.96M 0.84M
Capital stock 0.27M 0.18M 1.47M 0.96M 0.84M
Retained earnings -749.52400M -695.33600M -655.64000M -570.70400M -486.47000M
Other liab - 23.82M 4.03M - -
Good will - - 0.00000M 32.47M 32.47M
Other assets - 0.04M 1.06M 1.14M 1.14M
Cash 14.81M 14.22M 32.94M 12.60M 129.26M
Cash and equivalents - - - - -
Total current liabilities 13.42M 7.78M 16.62M 41.96M 38.70M
Current deferred revenue - - 0.30M 0.30M 0.30M
Net debt -9.41100M -6.59000M -23.56000M -3.86500M -121.30800M
Short term debt 1.00M 1.77M 1.82M 2.04M 1.70M
Short long term debt - - - 0.33M -
Short long term debt total 5.40M 7.63M 9.38M 8.73M 7.95M
Other stockholder equity 764.15M 722.05M 705.57M 672.30M 664.06M
Property plant equipment - 11.07M 21.74M 18.35M 13.16M
Total current assets 55.74M 53.10M 55.40M 97.74M 132.39M
Long term investments - - - - -
Net tangible assets - 26.76M 49.99M 68.58M 178.43M
Short term investments 37.75M 37.93M 12.09M 82.44M 0.00000M
Net receivables 2.44M 0.19M 3.00M - 0.00000M
Long term debt - - - 1.43M -
Inventory - 0.34M - - -
Accounts payable 1.86M 1.81M 4.33M 4.70M 3.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.06600M -0.12900M -0.02700M -0.01000M -4.15700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.96M 0.84M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -570.70400M -486.47000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.28M 0.04M 1.06M 1.14M 1.14M
Deferred long term asset charges - - - - -
Non current assets total 8.26M 11.12M 24.18M 53.46M 90.99M
Capital lease obligations 5.40M 7.63M 9.38M 6.97M 7.95M
Long term debt total - - - 1.43M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -23.96400M 66.06M -83.71400M 66.48M -65.59200M
Change to liabilities -5.49000M 0.82M -2.17800M -1.70700M 7.96M
Total cashflows from investing activities -23.96400M 66.06M -83.71400M 59.98M -85.08600M
Net borrowings - - 1.76M 1.76M 1.76M
Total cash from financing activities 43.17M 24.86M 1.94M 113.90M 5.48M
Change to operating activities - -16.08800M 3.81M -1.92700M -1.02700M
Net income -39.69600M -84.93600M -84.23400M -76.28200M -56.67100M
Change in cash -24.27400M 25.26M -116.79700M 111.06M -118.72000M
Begin period cash flow 38.83M 13.57M 130.37M 19.31M 138.03M
End period cash flow 14.55M 38.83M 13.57M 130.37M 19.31M
Total cash from operating activities -43.48300M -65.66500M -35.01900M -62.82000M -39.11100M
Issuance of capital stock 69.43M 25.48M 0.00100M 112.93M 0.00000M
Depreciation 4.58M 4.46M 5.60M 8.68M 2.36M
Other cashflows from investing activities - - - -0.19900M -10.25100M
Dividends paid - - - - -
Change to inventory - -16.08100M - -0.08100M -1.02700M
Change to account receivables 3.00M -3.00000M -3.00000M 0.08M 0.03M
Sale purchase of stock -26.25000M - 0.18M 17.93M 5.48M
Other cashflows from financing activities 22.46M -0.62300M 1.94M 0.97M 5.48M
Change to netincome - 33.07M 41.98M 7.34M 7.55M
Capital expenditures 0.13M 4.15M 1.34M 6.51M 19.49M
Change receivables - - - 0.08M 0.03M
Cash flows other operating - - 36.81M -2.63400M -0.33900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -116.79700M 111.06M -118.72000M
Change in working capital -5.89200M -18.26300M 1.63M -3.55300M 6.96M
Stock based compensation 3.05M 8.92M 8.19M 8.24M 8.87M
Other non cash items -5.52300M -6.55400M 0.88M 0.10M 0.69M
Free cash flow -43.61300M -69.81600M -36.35500M -69.32800M -58.60500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABEO
Abeona Therapeutics Inc		 -0.02 0.39% 5.14 - - 61.63 5.73 53.29 -0.5796
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc

6555 Carnegie Avenue, Cleveland, OH, United States, 44103

Key Executives

Name Title Year Born
Dr. Vishwas Seshadri M.B.A., Ph.D. Pres, CEO & Director 1976
Dr. Brendan M. O'Malley J.D., Ph.D. Sr. VP & Gen. Counsel 1969
Mr. Joseph Walter Vazzano Chief Financial Officer 1984
Mr. Brian Kevany Ph.D. VP, CTO & Head of Research NA
Mr. Gregory Gin VP of Investor Relations & Corp. Communications NA
Scott Santiamo Director of Corp. Communications NA
Ms. Alison Hardgrove VP of HR NA
Mr. Jon Voss VP & Head of Quality 1960
Dr. Vishwas Seshadri M.B.A., Ph.D. President, CEO & Director 1977
Mr. Joseph Walter Vazzano CPA Chief Financial Officer 1985

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.